Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled
The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE
/PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the...